Key result
Medical therapy fails to resolve swallowing-induced left atrial tachycardia refractory to mexiletine and amiodarone.
Why the study?
Swallowing-induced paroxysmal supraventricular tachycardia refractory to pharmacologic therapy including mexiletine and amiodarone is rare and not well characterized.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Swallowing-induced paroxysmal supraventricular tachycardia can originate from an ectopic left atrial focus and may be highly refractory to standard and investigational antiarrhythmic medications.
A 51-year-old female with a two-year history of palpitations associated with swallowing was evaluated by intracardiac electrophysiologic studies. Intracardiac recordings documented the presence of an ectopic left atrial focus induced by swallowing with no evidence of accessory pathway conduction. Gastrointestinal evaluation did not demonstrate any significant disorder. The tachycardia was refractory to all pharmacologic therapy including investigational therapy with mexiletine and amiodarone.
No takes yet. Share an insight, caveat, or question.
Ransbottom et al. (1988) conducted a case report in Swallowing-induced paroxysmal supraventricular tachycardia (n=1). Pharmacologic therapy (including mexiletine and amiodarone) was evaluated on Tachycardia resolution. Swallowing-induced paroxysmal supraventricular tachycardia originating from an ectopic left atrial focus was refractory to all pharmacologic therapy, including mexiletine and amiodarone.
Synapse has enriched 10 related papers. Consider them for comparative context: